Mifamurtide [clinicaltrials_resource:f5fde8d39973c1b801de2682e58dd94f]
A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 [clinicaltrials:NCT00000972]Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma [clinicaltrials:NCT00631631]Surveillance Study of Patients With Newly Diagnosed Osteosarcoma [clinicaltrials:NCT01194284]clinicaltrials:NCT01459484clinicaltrials:NCT02441309
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Mifamurtide [clinicaltrials_resource:f5fde8d39973c1b801de2682e58dd94f]
Bio2RDF identifier
f5fde8d39973c1b801de2682e58dd94f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f5fde8d39973c1b801de2682e58dd94f
identifier
clinicaltrials_resource:f5fde8d39973c1b801de2682e58dd94f
title
Mifamurtide
@en
type
label
Mifamurtide [clinicaltrials_resource:f5fde8d39973c1b801de2682e58dd94f]
@en